Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®
|
SAN DIEGO, Jan. 12, 2021 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Group’s 2021 BIG Innovation Awards for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). This annual business awards program recognizes organizations, products, and people that are bringing new ideas to life in innovative ways.
“As a female-led, female-focused company, we put women’s needs first and innovate for them. We know firsthand about the serious responsibility and impact of family planning,” said Saundra Pelletier, Chief Executive Officer, Evofem Biosciences. “Despite the 18 categories of contraception, nearly half of all U.S. pregnancies are still unplanned. Women need options they can and will use, including on-demand hormone-free prescription birth control. “Innovation is our opportunity to effect real change in women’s lives. We appreciate Business Intelligence Group for recognizing our efforts,” continued Pelletier. “Poverty elimination is profoundly impacted when a woman can choose when, if and how often she has children, and the best way to assist her is with innovation in birth control options.” Phexxi is designed to be used immediately before or up to an hour before intercourse. It was approved by the U.S. Food and Drug Administration in May 2020, and is now available in the U.S. by prescription. Phexxi works to maintain vaginal pH, which reduces sperm mobility, lowering the chance of sperm reaching the egg, and is the first non-hormonal contraceptive method created for women in decades. Organizations from across the globe submitted their recent innovations for consideration in the BIG Innovation Awards. Nominations were judged by a select group of business leaders and executives who volunteered their time and expertise to score submissions. About Evofem Biosciences Phexxi® is a registered trademark of Evofem Biosciences, Inc. About PHEXXI® IMPORTANT SAFETY INFORMATION WHAT ARE THE POSSIBLE SIDE EFFECTS OF PHEXXI® (lactic acid, citric acid, and potassium bitartrate) vaginal gel 1.8%, 1%, 0.4%? If you have had a history of repeated urinary tract infections or other urinary tract problems, avoid Phexxi®. The most common side effects were vaginal burning, vaginal itching, vaginal yeast infection, urinary tract infection, vaginal area discomfort, bacterial vaginosis, and vaginal discharge. Women also reported genital discomfort, pain while urinating, and vaginal pain. Some male partners reported genital discomfort. What else should I know about using Phexxi®? Phexxi® does not protect against any sexually transmitted diseases, including HIV. Avoid using Phexxi® with a vaginal ring. Contact your healthcare provider if you are experiencing severe genital irritation or discomfort or urinary tract symptoms. Avoid Phexxi® if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the ingredients in Phexxi®. Stop using Phexxi® if you develop an allergic reaction. Please see full Prescribing Information for Phexxi®, including Patient Information. Please report side effects by contacting Evofem Biosciences toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Forward Looking Statements About Business Intelligence Group Investor Relations Contact Media Contact
SOURCE Evofem Biosciences, Inc. | ||
Company Codes: NASDAQ-NMS:EVFM |
View original content to download multimedia:
